Fact CheckerSign in

NCT05568498RecruitingPhase 2

Probiotic Treatment for Depression and Associated Mood Disorders in Parkinson's Disease

Source: ClinicalTrials.gov · Last updated 8 May 2026

Brief summary (registry, in English)

This study evaluates the use of an oral multi-strain probiotic in the treatment of depression in individuals with Parkinson's Disease. Participants will be randomized to either a 12-week multi-strain probiotic treatment or placebo intervention.

Status (registry)
Recruiting
Phase (registry)
Phase 2
Study type
Interventional
Enrollment
60 (estimated)
First submitted
15 Jun 2022
Start date
20 Jan 2025
Primary completion date
31 Dec 2027
Lead sponsor
University of British Columbia
NCT number
NCT05568498

What you commit to

  • Study type: Interventional · Phase 2
  • Planned participants: 60
  • From 20 Jan 2025 to the primary completion date, 31 Dec 2027
  • 1 site in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Prior treatment

  • Change in the schedule of concurrent psychotherapy or brain stimulation for the treatment of mood or anxiety disorders in the last 4 weeks
  • Change in antidepressant or anxiolytic medication (including benzodiazepines) within the last 4 weeks
  • Change in Parkinson's medication within the last 2 weeks
  • Concurrent treatment for Parkinson's disease with Duodopa
  • Drug and/or substance abuse

Other illness

  • Neurological disease other than PD, including Alzheimer's disease, multi-infarct dementia, Huntington's disease, normal pressure hydrocephalus, a brain tumour, progressive supranuclear palsy, seizure disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma
  • A significant immune-compromised condition due to either a health condition or use of an immune suppressant (e.g., AIDS, lymphoma, chemotherapy treatment, patients undergoing long-term systemic corticosteroid or immunosuppressant treatment)
  • A known bleeding disorder
  • Current illness (e.g., a cold or flu-like symptoms) and infections (e.g., hepatitis, HIV, gastroenteritis, fungal, or parasitic infections)
  • Allergy to corn starch or corn
  • New onset of significant psychiatric symptoms following DBS procedure that are considered likely related
  • Unstable medical conditions or serious disease/conditions (e.g., cancer undergoing active treatment, poorly controlled diabetes)
  • The patient, in the opinion of the Investigator, is unable to adhere to the requirements of the study. This includes any patient who, in the judgment of the Investigator, is likely to be noncompliant during the study, or unable to cooperate because of a significant language barrier or cognitive impairment

Other

  • Atypical Parkinsonism
  • Active suicidality
  • Active psychosis
  • Cognitive score (MoCA) of \< 21 in the "ON" state
  • Severe depression (BDI-II score \> 28 in the "ON" state)
  • Probiotic, Saccharomyces boulardii and/or antibiotic use in the past 3 months (yogurt, kefir, and other probiotic-containing foods are allowed)
  • The use of natural health products that affect depression (e.g., St. John's Wort, passion flower, gaba, 5-htp, kava, bacopa, efa's)
  • Change in Deep Brain Stimulation (DBS) stimulation parameters in the last 4 weeks
  • Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the trial

Who the study is looking for

  • Confirmed diagnosis of Parkinson's disease based on UK Brain Bank criteria
  • Between the ages of 40-80 years
  • Mild to Moderate PD (Hoehn and Yahr stage between 1-3 in the "ON" state)
  • Mild to moderate depression (BDI-II score of 14-28 in the "ON" state)
  • Women of childbearing potential must agree to use a medically approved method of birth control (e.g., hormonal contraceptives, intrauterine devices, vasectomy/tubal litigation, barrier methods and double barrier method) and must have negative pregnancy test results at screening and baseline
  • Willingness to maintain current physical activity levels during study period
  • English proficiency

Age in the registry: 40 years to 80 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Pacific Parkinson's Research Centre
Coordinator of this site? Confirm its status
VancouverCanadaRecruiting

This page is information, not medical advice. Discuss any trial with your doctor.